

WO9406433

Publication Title:

NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS

Abstract:

Abstract of WO9406433

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, ether or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Data supplied from the esp@cenet database - Worldwide


Courtesy of <http://v3.espacenet.com>



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/557	A1	(11) International Publication Number: WO 94/06433 (43) International Publication Date: 31 March 1994 (31.03.94)
(21) International Application Number: PCT/US93/08472 (22) International Filing Date: 9 September 1993 (09.09.93) (30) Priority data: 07/948,056 21 September 1992 (21.09.92) US (71) Applicant: ALLERGAN, INC. [US/US]; 2525 Dupont Drive, Post Office Box 19534, Irvine, CA 92713-9534 (US). (72) Inventors: WOODWARD, David, F. ; 23152 Tulip Street, El Toro, CA 92630 (US). ANDREWS, Steven, W. ; 3931 Cedron Street, Irvine, CA 92714 (US). BURK, Robert, M. ; 3901 Park View, #17D, Irvine, CA 92715 (US). GARST, Michael, E. ; 2433 Vista Hogar, Newport Beach, CA 92660 (US).		(74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, Post Office Box 19534, Irvine, CA 92713-9534 (US). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS

**(57) Abstract**

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, ether or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CJ	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS

5 Field of the Invention

The present invention relates to cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, hydryl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, ether or thioether groups, e.g., 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Background of the Invention

25 Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.

30

Glaucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. For example, primary glaucoma in adults (congenital glaucoma)

-2-

may be either open-angle or acute or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or an enlarged cataract.

5

The underlying causes of primary glaucoma are not yet known. The increased intraocular tension is due to the obstruction of aqueous humor outflow. In chronic open-angle glaucoma, the anterior chamber and its anatomic
10 structures appear normal, but drainage of the aqueous humor is impeded. In acute or chronic angle-closure glaucoma, the anterior chamber is shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation
15 of the pupil may push the root of the iris forward against the angle, and may produce pupillary block and thus precipitate an acute attack. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of various degrees of severity.

20

Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm. Inflammatory disease of the anterior segment
25 may prevent aqueous escape by causing complete posterior synechia in iris bombe and may plug the drainage channel with exudates. Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular
30 hemorrhage.

Considering all types together, glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of

- 3 -

vision. In cases where surgery is not indicated, topical β -adrenoreceptor antagonists have traditionally been the drugs of choice for treating glaucoma.

5 Prostaglandins were earlier regarded as potent ocular hypertensives; however, evidence accumulated in the last two decades shows that some prostaglandins are highly effective ocular hypotensive agents and are ideally suited for the long-term medical management of glaucoma. (See, 10 for example, Starr, M.S., *Exp. Eye Res.*, 1971, 11, P.P. 170-177; Bito, L. Z. Biological Protection with Prostaglandins Cohen, M. M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252; and Bito, L. Z., Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, 15 A. H. eds., New York, Grune & Stratton, 1984, pp. 477-505). Such prostaglandins include $\text{PGF}_2\alpha$, $\text{PGF}_1\alpha$, PGE_2 , and certain lipid-soluble esters, such as C_1 to C_5 alkyl esters, e.g. 1-isopropyl ester, of such compounds.

20 In the United States Patent No. 4,599,353 certain prostaglandins, in particular PGE_2 and $\text{PGF}_2\alpha$ and the C_1 to C_5 alkyl esters of the latter compound, were reported to possess ocular hypotensive activity and were recommended for use in glaucoma management.

25 Although the precise mechanism is not yet known, recent experimental results indicate that the prostaglandin-induced reduction in intraocular pressure results from increased uveoscleral outflow [Nilsson et al., Invest. Ophthalmol. Vis. Sci. 28(suppl), 284 (1987)]. 30

The isopropyl ester of $\text{PGF}_2\alpha$ has been shown to have significantly greater hypotensive potency than the parent compound, which was attributed to its more effective

- 4 -

penetration through the cornea. In 1987 this compound was described as "the most potent ocular hypotensive agent ever reported." [See, for example, Bito, L. Z., Arch. Ophthalmol. 105, 1036 (1987), and Siebold et al., Prodrug 5, 3 (1989)].

5

Whereas prostaglandins appear to be devoid of significant intraocular side effects, ocular surface (conjunctival) hyperemia and foreign-body sensation have been consistently associated with the topical ocular use of such compounds, in particular $\text{PGF}_{2\alpha}$ and its prodrugs, e.g. its 1-isopropyl ester, in humans. The clinical potential of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma, is greatly limited by these side effects.

15

Certain phenyl and phenoxy mono, tri and tetra nor prostaglandins and their 1-esters are disclosed in European Patent Application 0,364,417 as useful in the treatment of glaucoma or ocular hypertension.

20

In a series of co-pending United States patent applications assigned to Allergan, Inc. prostaglandin esters with increased ocular hypotensive activity accompanied with no or substantially reduced side-effects are disclosed. The co-pending USSN 386,835 (filed 27 July 1989), relates to certain 11-acyl-prostaglandins, such as 11-pivaloyl, 11-acetyl, 11-isobutyryl, 11-valeryl, and 11-isovaleryl $\text{PGF}_{2\alpha}$. Intraocular pressure reducing 15-acyl prostaglandins are disclosed in the co-pending application USSN 357,394 (filed 25 May 1989). Similarly, 11,15- 9,15- and 9,11-diester of prostaglandins, for example 11,15-dipivaloyl $\text{PGF}_{2\alpha}$ are known to have ocular hypotensive activity. See the co-pending patent applications USSN No. 385,645 filed 27 July 1990, now U.S. Patent No. 4,494,274; 584,370 which is a

30

- 5 -


continuation of USSN No. 386,312, and 585,284, now U.S. Patent No. 5,034,413 which is a continuation of USSN 386,834, where the parent applications were filed on 27 July 1989. The disclosures of these patent applications are
5 hereby expressly incorporated by reference.

Summary of the Invention

We have found that certain cyclopentane heptanoic
10 acid, 2-cycloalkyl or arylalkyl derivatives wherein the carboxylic acid group is replaced by a non-acidic substituent have pronounced effects on smooth muscle and are potent ocular hypotensive agents. We have further found that such compounds may be significantly more potent than their
15 respective parent compounds and, in the case of glaucoma surprisingly, cause no or significantly lower ocular surface hyperemia than the parent compounds.

The present invention relates to methods of treating
20 cardiovascular, pulmonary-respiratory, gastrointestinal, reproductive and allergic diseases, shock and ocular hypertension which comprises administering an effective amount of a nonacidic derivative of cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl represented by the formula I

25




wherein A is an alkylene or alkenylene radical having from two to six carbon atoms, e.g. about four to five carbon atoms,
30 which radical may be substituted with one or more hydroxy,

- 6 -

oxo, alkyloxy or alkylcarboxy groups, and B is a cycloalkyl
 radical having from three to seven carbon atoms, e.g. about
 five to six carbon atoms, or an aryl radical, selected from the
 group consisting of hydrocarbyl aryl and heteroaryl radicals
 5 wherein the heteratom is selected from the group consisting
 of nitrogen, oxygen and sulfur atoms, and R_1 , R_2 and X are as
 defined below. For example, A may be a straight chain
 alkylene radical, e.g. pentylene, or alkenylene radical, e.g. 3-
 hydroxy-1-pentylenyl, and B may be selected from the
 10 group consisting of cyclopentyl, cyclohexyl, phenyl, thienyl,
 furanyl, pyridyl, etc. B may also be substituted by radicals
 represented by Y, as defined below.


More preferably the method of the present invention
 15 comprises administering a non-acidic derivative of
 cyclopentane heptanoic acid, 2-(phenyl alkyl) represented
 by the formula II



20

wherein y is 0 or 1 and either the α or ω chain may be
 unsaturated, Y is a radical selected from the group consisting
 of halo, e.g. fluoro, chloro, etc., nitro, amino, thiol, hydroxy,
 alkyloxy, alkylcarboxy, etc. and n is 0 or an integer of from
 25 1 to about 3 and the symbols R_1 , R_2 , R_3 and X are as defined
 below. Preferably the non-acidic derivative used in the
 above method of treatment is a compound of formula (III).


-7-



wherein hatched lines indicate α configuration, solid triangles are used to indicate β configuration; the dashed bonds represent a single bond or a double bond which can be in the cis or trans configuration; X is a radical selected from the group consisting of halo, hydryl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, alkoxy (ether) and thio ether radicals; one of R₁ and R₂ is =O, -OH or a -O(CO)R₆ group, and the other one is -OH or -O(CO)R₆, or R₁ is =O and R₂ is H; R₃ is =O, OH or O(CO) R₆; wherein R₆ is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or -(CH₂)_mR₇ wherein m is 0-10, and R₇ is an aliphatic ring from about 3 to about 7 carbon atoms, or an aryl or heteroaryl ring, as defined above; or a pharmaceutically acceptable salt thereof. Preferably R₁, R₂ and R₃ are -OH.

In another aspect, the present invention relates to a method of treating cardiovascular, pulmonary-respiratory, gastrointestinal, reproductive and allergic diseases, shock and ocular hypertension which comprises administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (IV)

- 8 -



wherein the symbols and substituents are as defined above,
in combination with a pharmaceutical carrier.

5


In a further aspect, the present invention relates to
pharmaceutical compositions comprising a therapeutically
effective amount of a compound of formulae (I), (II), (III),
or (IV) wherein the symbols have the above meanings, or a
10 pharmaceutically acceptable salt thereof in admixture with a
non-toxic, pharmaceutically acceptable liquid vehicle.

In a still further aspect, the present invention relates
to nonacidic cyclopentane heptanoic acid, 5-cis-2-(3-
15 hydroxy-5-phenyl-1-trans-pentyl) derivatives of the above
formulae, wherein the substituents and symbols are as
defined hereinabove, or a pharmaceutically acceptable salt
of such compounds.

- 9 -

Detailed Description of the Invention


The present invention relates to the use of cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl
 5 derivatives as therapeutic agents, e.g. as ocular hypotensives. These therapeutic agents are represented by compounds having the formula I,



10


as defined above. The preferred nonacidic cyclopentane heptanoic acid, 2-(phenyl alkyl) derivatives used in accordance with the present invention are encompassed by the following structural formula (II)

15




20

wherein the substituents and symbols are as hereinabove defined. More preferably the nonacidic derivatives are represented by formula (III).




-10-

wherein the substituents and symbols are as defined above.
 More preferably, the nonacidic derivatives utilized in the
 present invention are compounds represented by the
 5 formula (IV)



wherein the substituents and the symbols are as defined
 10 above.

Most preferably the present invention utilizes the
 novel nonacidic derivatives of the formula (V)



15

and their 9- and/or 11- and/or 15-esters.

20 In all of the above formulae, as well as in those
 provided hereinafter, the dotted lines on bonds between
 carbons 5 and 6 (C-5), between carbons 13 and 14 (C-13),
 between carbons 8 and 12 (C-8), and between carbons 10
 and 11 (C-10) indicate a single or a double bond which can
 25 be in the cis or trans configuration. If two solid lines are

- 11 -

used that indicates a specific configuration for that double bond. Hatched lines at positions C-9, C-11 and C-15 indicate the α configuration. If one were to draw the β configuration, a solid triangular line would be used.

5

In the compounds used in accordance with the present invention, compounds having the C-9 or C-11 or C-15 substituents in the α or β configuration are contemplated. As hereinabove mentioned, in all formulas provided herein
10 broken line attachments to the cyclopentane ring indicate substituents in the α configuration. Thickened solid line attachments to the cyclopentane ring indicate substituents in the β configuration. Also, the broken line attachment of the hydroxyl group or other substituent to the C-11 and C-
15 15 carbon atoms signifies the α configuration.

For the purpose of this invention, unless further limited, the term "alkyl" refers to alkyl groups having from one to ten carbon atoms, the term "cycloalkyl" refers to
20 cycloalkyl groups having from three to seven carbon atoms, the term "aryl" refers to aryl groups having from four to ten carbon atoms. The term "saturated or unsaturated acyclic hydrocarbon group" is used to refer to straight or branched chain, saturated or unsaturated hydrocarbon groups having
25 from one to about 6, preferably one to about 4 carbon atoms. Such groups include alkyl, alkenyl and alkynyl groups of appropriate lengths, and preferably are alkyl, e.g. methyl, ethyl, propyl, butyl, pentyl, or hexyl, or an isomeric form thereof.

30

The definition of R_6 may include a cyclic component, $-(CH_2)_mR_7$, wherein n is 0-10, R_7 is an aliphatic ring from about 3 to about 7 carbon atoms, or an aromatic or heteroaromatic ring. The "aliphatic ring" may be saturated

-12-

or unsaturated, and preferably is a saturated ring having 3-7 carbon atoms, inclusive. As an aromatic ring, R₇ preferably is phenyl, and the heteroaromatic rings have oxygen, nitrogen or sulfur as a heteroatom, i.e., R₇ may be thienyl, furanyl, pyridyl, etc. Preferably m is 0-4.

X may be selected from the group consisting of: -H, -F, -I, -NO₂, -OH, -OH, $\begin{array}{c} \text{O} \\ || \\ -\text{C}-\text{N}(\text{R}_4)(\text{R}_4) \end{array}$, -N(R₄)(R₄), =N-OH, -C≡N, -SH, -SR₅ and -OR₅ wherein R₄ is hydrogen or C₁ to C₃ alkyl, and R₅ is C₁ to C₃ alkyl. Preferably R₄ is hydrogen.

Preferred representatives of the compounds within the scope of the present invention are the compounds of formula V wherein X is -OH, i.e. cyclopentane heptenol, 5-cis-2-(3-αhydroxy-5-phenyl-1-trans-pentenyl)-3, 5-dihydroxy, [1_α, 2_β, 3_α, 5_α] and the 9- and/or 11- and/or 15-esters of this compound. (The numbered designations in brackets refer to the positions on the cyclopentane ring.)

The following novel compounds may be used in the pharmaceutical compositions and the methods of treatment of the present invention.

- (1) cyclopentane heptenol-5-cis-2-(3-αhydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α, 2_β, 3_α, 5_α]
- (2) cyclopentane heptenamide-5-cis-2-(3-αhydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α, 2_β, 3_α, 5_α]

-13-

- (3) cyclopentane N,N-dimethylheptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 5 (4) cyclopentane heptenyl methoxide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 10 (5) cyclopentane heptenyl fluoride-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 15 (6) cyclopentane heptenyl nitrate-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 20 (7) cyclopentane heptenyliodide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 25 (8) cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- (9) cyclopentane heptenecyanide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
- 30 (10) cyclopentane hepteneazide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

- 14 -

- 5 (11) cyclopentane heptene-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}] (Note when X is -H, i.e. hydryl, the correct designation is heptene.)
- (12) cyclopentane N-isopropyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
- 10 (13) cyclopentane N-ethyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
- 15 (14) cyclopentane N-methyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
- 20 (15) cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
- (16) cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
- 25 (17) cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]

30 A pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. Such salts are those formed with

-15-

pharmaceutically acceptable cations, e.g., alkali metals, alkali earth metals, etc.

Pharmaceutical compositions may be prepared by
5 combining a therapeutically effective amount of at least one
compound according to the present invention, or a
pharmaceutically acceptable salt thereof, as an active
ingredient, with conventional pharmaceutically-acceptable
excipients, e.g. an ophthalmically-acceptable vehicle, and by
10 preparation of unit dosage forms suitable for pharmaceutical
use, e.g. topical ocular use. The therapeutically efficient
amount typically is between about 0.0001 and about 5%
(w/v), preferably about 0.001 to about 1.0% (w/v) in liquid
formulations.

15

-16-

For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.

Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

-17-

In a similar vein, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.

The ingredients are usually used in the following amounts:

<u>Ingredient</u>	<u>Amount (% w/v)</u>
active ingredient	about 0.001-5
preservative	0-0.10
vehicle	0-40
tonicity adjustor	0-10
buffer	0.01-10
pH adjustor	q.s. pH 4.5-7.5
antioxidant	as needed
surfactant	as needed
purified water	as needed to make 100%

The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper,

- 18 -

to facilitate application to the eye. Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution. One package may
5 contain one or more unit doses.

Especially preservative-free solutions are often formulated in non-resealable containers containing up to about ten, preferably up to about five units doses, where a
10 typical unit dose is from one to about 8 drops, preferably one to about 3 drops. The volume of one drop usually is about 20-35 μ l.

The invention is further illustrated by the following
15 non-limiting Examples.

-19-

Example 1

Radioligand Binding Studies

- 5 The Radioligand binding studies reported in Figures 1 to 3 were performed on plasma membrane preparations from the rat colon. Tissues were homogenized in buffer (0.25 M sucrose, 50 mM TRIS: pH 7.4) with a polytron homogenizer for 3 secs at setting 7. The homogenate was
10 centrifuged at 200g, the supernatant was filtered through gauze, and the filtrate centrifuged at 177,000g for 40 min. Enriched plasma membrane fractions were subsequently prepared using two-step discontinuous gradients. The
15 177,000g pellet was suspended in homogenization buffer and layered over a cushion of 0.842 M sucrose for radiolabelled 17-phenyl PGF₂ α studies. Centrifugation was then performed at 112,700g for 2 hr. The bands at the interface of the sucrose layers were carefully aspirated and centrifuged at 304,000g for 40 min. Radioligand binding
20 assays were performed on the pellets, which were suspended with the aid of sonication. Studies with radiolabelled 17-phenyl PGF₂ α were performed in buffer containing 50 mM TRIS-HCl and 2.5 mM Mn Cl₂ at pH 5.75.
- 25 Competition studies were performed vs. 5nM³H-17-phenyl PGF₂ α in a total volume of 200 μ l. Protein concentrations were approximately 40 μ g/ml for the colon membrane homogenates. Non-specific binding was determined by 10 μ M of the corresponding unlabelled
30 ligand. Studies were terminated by the addition of ice-cold buffer and rapid filtration through Whatman GF/B filters using a Brandel cell harvester.

-20-

Figure 1 shows that prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) and 17-phenyl $PGF_{2\alpha}$ both potently displace 3H -17-phenyl $PGF_{2\alpha}$ from its receptor in a dose-related manner. In contrast, 3H -17-phenyl $PGF_{2\alpha}$ is not displaced when the terminal -COOH group is replaced by an amine or a methylamide group. See Fig. 2 wherein cyclopentane hepteneamine, 5-cis-2-(3-hydroxy-5-phenyl-1-trans-pentenyl)-3, 5-dihydroxy, [1α , 2β , 3α , 5α] and the N-methyl derivative thereof are compared to 17-phenyl $PGF_{2\alpha}$ for their ability to displace 3H -17-phenyl $PGF_{2\alpha}$ from its receptor. A further example is provided in Fig. 3 where 16-m-chlorophenoxy $PGF_{2\alpha}$ potently displaces 3H -17-phenyl $PGF_{2\alpha}$ but the potent displacement observed for 16-m-chlorophenoxy $PGF_{2\alpha}$ is greatly reduced when the terminal -COOH group is replaced by -CONH₂ as in the compound cyclopentane heptenamide, 5-cis-2-(3-hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5-dihydroxy, [1α , 2β , 3α , 5α].

-21-

Example 2**Ca²⁺ Signal in Swiss 3T3 Cells**

5 Measurement of intracellular [Ca²⁺] was achieved by
incorporating the Ca²⁺-sensitive fluorescent probe Fura-2
AM into Swiss 3T3 cells in suspension as described in
Woodward et al. Advances in Prostaglandin, Thromboxane
and Leukotriene Research 21:367, 1990. Fluorescence was
10 measured in a Perkin-Elmer LS-5 spectrophotometer at
excitation and emission wavelengths of 340 and 492 nm,
respectively. Each experimental determination employed
10⁶ cells suspended in Schmuells buffer. For studies in
Ca²⁺-free Schmuells buffer, each cuvette also contained
15 0.4mM EGTA. Calibration of the Fura 2 signal was as
previously described for Quin 2 and Fura 2 Yamaguchi et al.
J. Biological Chemistry 263: 10745, 1988. Briefly the cells
were lysed with digitonin (10 µl x 100 mg/ml in DMSO).
EGTA (100 mM) and sufficient 10N NaOH to adjust the pH to
20 8.5 were then successively added to obtain minimum
fluorescence.

The effects of the compounds examined on
intracellular [Ca²⁺] are compared as the concentration
25 required to produce 50% of the maximal PGF_{2α} response
(Table 1). Note that replacement of the terminal -COOH
group by a non-acidic substituent universally results in a
dramatic reduction in activity.

-22-

Table 1Effect on $[Ca^{2+}]$ in Swiss 3T3 Cells

<u>PARENT COMPOUND</u> (1-DERIVATIVE)	<u>E.C.₅₀[nM]</u>
PGF _{2α}	50
A(CONH ₂)	
A(CON(CH ₃) ₂)	65000
A(OH)	>10,000
A(OCH ₃)	>10,000
A(F)	>10,000
A(NO ₂)	>10,000
A(NH ₂)	>10,000
A(I)	>10,000
A(CN)	>10,000
A(N ₃)	>10,000
A(CH ₃)	>10,000
17-phenyl PGF _{2α}	13
B(CONH ₂)	900
B(OH)	>10,000

5

A is cyclopentane heptenoic acid, 5-cis-2-(3- α -hydroxy-1-trans-octenyl)-3, 5-dihydroxy, [1 α , 2 β , 3 α , 5 α]

-23-

B is cyclopentane heptanoic acid, 5-cis-2-(3- α -hydroxy-5-phenyl-1-trans-pentenyl)-3, 5-dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]

-24-

Example 3DNA Synthesis in Swiss 3T3 Cells

5 Swiss mouse 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) low glucose and supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine and 1% antibiotic-antimycotic 100X. The cultures were incubated in 5% CO₂ in air at 37°C. Confluent cultures
10 were trypsinized and plated in quadruplicate cultures for experiments. Cells were plated at 1×10^5 cells per 35 mm well in DMEM containing 10% FBS in 6-well cluster plates and allowed to become confluent in 3 days. The cells were then made quiescent by washing them with Hank's balanced
15 salt solution (HBSS) and incubating them for 24 hours in DMEM with 0.5% FBS. The cultures were then refed fresh DMEM containing 0.5% FBS and various concentrations of the compounds of interest. All compounds were dissolved in absolute ethanol, diluted with sterile filtered normal saline
20 and added to the medium so that the final ethanol control cultures were incubated in medium containing 0.01% or less. The vehicle control cultures were incubated in medium containing 0.01% ethanol in saline. Cultures were incubated for 22 hours before pulse-labeling with (³H)-TdR).

25 Pulse-labeling of the cultures consisted of collecting the conditioned, drug-treated or control containing media, then adding 1 μ Ci/ml [³H]-TdR and incubating the cultures in the [³H]-TdR containing medium for 5 hours. The cells were
30 then washed with phosphate buffered saline and fixed with 6% trichloroacetic acid (TCA). The cells were scraped from the culture wells and transferred to tubes. Each well was rinsed with 6% TCA and the rinse was added to the appropriate tubes. Each well was rinsed with 6% TCA and

-25-

the rinse was added to the appropriate tubes. After centrifugation at 2800 RPM for 20 minutes at room temperature, an aliquot of the supernatant containing unincorporated [^3H]-TdR(S1) was transferred to scintillation
5 tubes. Radioactivity was measured by liquid-scintillation counting using Beckman HP cocktail. The remainder S1 supernatant was decanted and 3% perchloric acid (PCA) was added to the cell pellet. The DNA was denatured by placing the tubes in heating blocks at 95° C for 20 minutes, followed
10 by placing the tubes in an ice bath for 15 minutes. After centrifugation as before, an aliquot of the supernatant containing [^3H]-TdR incorporated into DNA (S2) was assayed for radioactivity by scintillation counting.

15 An aliquot of the remaining S2 supernatant was assayed for quantity of DNA by the diphenylamine method. DNA standards, prepared from salmon testes DNA, and the samples were mixed with the diphenylamine reagent and incubated in a water bath with shaking at 30° C for 6-24
20 hours. The diphenylamine reagent was prepared with 1.5% diphenylamine in glacial acetic acid and per 100 ml of the solution, by adding 1.5 ml of concentrated sulfuric acid and 0.5 ml of 1.6% acetaldehyde. Absorbance of the DNA standards and samples were measured in a Beckman
25 Biomek spectrophotometer at 600 nM wavelength.

The data was expressed as CPM([^3H]-TdR incorporated into DNA) per ug DNA and the mean of the quadruplicate samples was obtained for each experiment. The results
30 were presented as per cent of the vehicle control.

Table 2 shows that although $\text{PGF}_{2\alpha}$ and 17-phenyl $\text{PGF}_{2\alpha}$ potently increased DNA synthesis, replacement of the -COOH group by -OH resulted in a complete loss of activity.

-26-

These results imply that the potential for fibrosis associated with prostanoids may be avoided by the nonacidic derivatives of this invention.

-27-

Table 2**Inhibition of DNA Synthesis**

5 (E.C.₅₀ Values are 50% of maximal DNA synthesis response)

<u>PARENT COMPOUND</u> (1-DERIVATIVE)	<u>E.C.₅₀ [nM]</u>
PGF _{2α}	45
A(OH)	>10,000
17-phenyl PGF _{2α}	50
B(OH)	>10,000

-28-

Example 4Vasorelaxation

5 The external rabbit jugular vein was used for
vasorelaxation studies. A 3 mM ring was suspended in a 5
ml organ bath containing Krebs buffer and 1 μ M
indomethacin. The ring was pre-contracted with 10^{-5} M
histamine to enable evaluation of vasorelaxation.

10

Results of these studies are given in Table 3. Potent
vasodilator properties were apparent, the isopropylamide
substituent unexpectedly provided a vasodilator with very
high activity.

-29-

Table 3Vasorelaxation Responses5 (E.C.₂₅ is the dose [M] to cause a 25% relaxation)

<u>COMPOUND</u> (1-DERIVATIVE)	<u>E.C.₂₅ [nM]</u>
17-phenyl PGF _{2α}	57
A(OH)	40
A(CONH ₂)	287
A(CON(CH ₃) ₂)	73
A(CONH(isopropyl))	7.9

-30-

Example 5**Smooth Muscle Stimulation**

5 The ability of the nonacidic derivatives of this
invention to contract a variety of smooth muscle
preparations were determined. Isolated smooth muscle
responses were evaluated in the conventional way, using an
organ bath and a force displacement transducer. The
10 preparations are the cat iris, ileum (guinea-pig and chick),
rat colon, and rat aorta. Table 4 summarizes the results.

15 It can be seen that replacement of the carboxylic acid
moiety results in compounds with minimal or absent
contractile activity on the arterial smooth muscle (aorta) or
ileum preparations. In contrast, surprisingly potent activity
is retained for the cat iris and the rat colon.

Table 4

Comparison of Smooth Muscle Stimulant Properties

E.C.50 values represent the concentration [M]
required to produce 50% of the maximal PGF₂ α effect.

Compound (1-DERIVATIVE)	Cat Iris	Guinea Pig Ileum	Chick Ileum	Rat Colon	Rat Aorta
PGF ₂ α	20	1900	1600	13	2,000
A(CONH ₂)	21	>10,000	>10,000	--	>10,000
A(CON(CH ₃) ₂)	450	--	--	--	--
A(OH)	60	>10,000	>10,000	81	4400
A(OCH ₃)	60	--	--	--	--
A(F)	1500	--	--	--	--
A(NO ₂)	1400	--	--	--	--
A(NH ₂)		>10,000	--	--	>10,000
A(I)	700	--	--	--	--
A(CN)	420	--	--	--	--
A(N ₃)	1000	--	--	--	--
A(CH ₃)	230	--	--	--	--
17-phenyl PGF ₂ α	11	--	--	--	--

Table 4 (Continued)

Comparison of Smooth Muscle Stimulant Properties

<u>Compound</u>	<u>Cat Iris</u>	<u>Guinea Pig Ileum</u>	<u>Chick Ileum</u>	<u>Rat Colon</u>	<u>Rat Aorta</u>
B(OH)	62	>10,000	>10,000	--	>10,000
B(CONH ₂)	121	>10,000	>10,000	--	>10,000
B(CONH CH ₃)	56	>10,000	>10,000	--	>10,000
B(CON(CH ₃) ₂)	670	--	--	--	>10,000
B(CONH C ₂ H ₅)	34	>10,000	--	--	--
B(CONH isopropyl)	175	>10,000	>10,000	--	>10,000
B(NH ₂)	33	--	--	--	--
16-m-chlorophenoxy PGF ₂ α	0.7	>10,000	525	--	8060
C(OH)	4.2	>10,000	>10,000	--	--
C(CONH ₂)	30	>10,000	>10,000	--	>10,000
13,14 dihydro 17-phenyl PGF ₂ α	66	>10,000	525	--	--
D(OH)	690	>10,000	>10,000	--	--

C is cyclopentane heptenoic acid, 5-cis-2-(3- α -hydroxy-4m-chlorophenoxy-1-trans-butenyl)-3, 5-dihydroxy, [1 α , 2 α , 4 α , 5 β]

D is cyclopentane heptenoic acid, 5-cis-2-(3- α -hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1 α , 2 α , 4 α , 5 β]

-33-

Example 6Intraocular Pressure

5 Intraocular pressure was measured by
pneumatometry in male and female Beagle dogs (10-15
kg). Studies were performed in conscious animals trained to
accept pneumatometry. Drugs were administered
topically to one eye in a 25 μ l volume drop, the contralateral
10 eye received vehicle as a control. Statistical analysis was by
Student's paired t test.

Replacement of the -COOH by a diverse variety of
substituents resulted in potent ocular hypotensive agents,
15 despite the inability of these agents to bind to prostanoid
receptors or elicit a Ca^{2+} second message as shown above.
The intraocular pressure results are summarized in Table 5.

-34-

Table 5

**Effect of Nonacid Derivatives on
Intraocular Pressure**

**IOP (mm Hg) at Predetermined
Times (HR) After Dosing**

COMPOUND (1-DERIVATIVE)	DOSE	2	4	6	24
17-phenyl PGF ₂ α	0.01%	+1.6	-2.7**	-3.0**	--
17-phenyl PGF ₂ α	0.1%	-2.2	-4.8**	-5.9**	--
B(OH)	0.01%	-0.7	-1.7	-2.2	--
B(OH)	0.1%	-2.4	-5.1	-4.7**	--
B(NH ₂)	0.1%	-0.9	-1.0	-2.3**	--
B(CONH ₂)	0.1%	-2.7*	-4.1*	-5.7**	--
B(CON(CH ₃) ₂)	0.1%	-2.8**	-4.4**	-4.9**	--
B(isopropylamide)	0.1%	-2.0	-5.1**	-5.6**	-3.7**
B(-methylethylamide)	0.1%	-0.3	-3.3**	-2.8*	3.4**
B(ethylethylamide)	0.1%	-0.3	-2.8**	-4.9**	-2.8**
16-m-chlorophenoxy PGF ₂ α	0.1%	-1.5	-3.4**	-1.6	--
C(OH)	0.01%				
C(OH)	0.1%	-3.1**	-3.2**	-4.7**	

* p < 0.05

** p < 0.01

n=6

-35-

Table 5 (Continued)Effect of Compounds Analogs on
Dog Intraocular PressureIOP (mm Hg) at Predetermined
Times (HR) After Dosing

COMPOUND (1-DERIVATIVE)	DOSE	2	4	6	24
C(CONH ₂)	0.01%				
C(CONH ₂)	0.1%	-1.5	-17**	-2.7*	

* p < 0.05

** p < 0.01

n=6

-36-

Example 7Inhibition of Neuronally Mediated Contraction
of the Vas Deferens

5

Field stimulation of the isolated guinea-pig vas deferens results in contraction of the tissue. This provides a useful preparation for evaluating the effect of drugs on sympathetic neuronal transmission. 17-phenyl PGF_{2α} produced inhibition of this response whereas replacement of the -COOH moiety in this series of compounds resulted in either reduction or abolition of this activity (See Table 6 below).

15

Table 6

Inhibition of Contraction of the
Field-Stimulated Guinea Pig Vas Deferans

5

E.C.₅₀ values represent the concentration [nM]
required to produce 50% of the maximal PGE₂ effect.

<u>COMPOUND</u>	<u>E.C.₅₀[nM]</u>
(1-DERIVATIVE)	
17-phenyl PGF _{2α}	282
B(CONH ₂)	>10,000
B(OH)	--
B(NH ₂)	>10,000
B(CONH CH ₃)	2,188
B(CON(CH ₃) ₂)	>10,000

10

-38-

Example 8

Cyclopentane methylheptenoate-5-cis-2
(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

To a stirred solution of cyclopentane heptenoic acid, 5-
10 cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-
3,5-dihydroxy, [1 α , 2 β , 3 α , 5 α] (24 mg. 0.0565 mmol) in
acetone (0.6 ml) at room temperature was added 1, 8
diazabicyclo [5.4.0.] undec-7-ene (DBU) (40, ul, 0.27 mmol)
and methyl iodide (20 ul, 0.32 mmol). The reaction turned
15 yellow with the DBU addition. The reaction was maintained
at room temperature for 6.5 hours, then was diluted with
ethyl acetate (30 ml) and filtered through a plug of celite
with the aid of ethyl acetate. After concentration in vacuo,
the residue was flushed with ethylacetate (EtOAc) through a
20 20 mm x 160 mm column of silica to give the desired
methyl ester.

-39-

Example 9

Cyclopentane heptenamide-5-cis-2-
(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

10 A mixture of the methyl ester of Example 8 (9.2 mg, 0.0222 mmol) and NH₄Cl (10 mg, 0.187 mmol) in NH₃ was heated at 80°C. for 12 hours. After cooling to room temperature, the solvents were evaporated and the residue was subjected to column chromatography to provide the named amide as 7.2 mg of a clear, colorless liquid.

-40-

Example 10

Cyclopentane methyl heptenoate-5-cis-2
(3- α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3,5 dihydroxy, [1 α ,2 β ,3 α ,5 α]

To a stirred solution of cyclopentane heptenoic acid, 5-
cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5
10 dihydroxy, [1 α ,2 β ,3 α ,5 α] (24 mg. 0.0565 mmol) in acetone
(0.6 ml) at room temperature was added DBU (40, μ l, 0.27
mmol) and methyl iodide (20 μ l, 0.32 mmol). The reaction
turned yellow with the DBU addition. The reaction was
maintained at room temperature for 6.5 hours, then was
15 diluted with ethyl acetate (30 ml) and filtered through a
plug of celite with the aid of ethyl acetate. After
concentration in vacuo, the residue was flushed with
ethylacetate (EtOAc) through a 20 mm x 160 mm column of
silica to give the desired methyl ester.

20

-41-

Example 11

Cyclopentane heptenamide -5-cis
-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3,
5 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

10 A solution of the methyl ester of Example 10 and
NH₄Cl in NH₃ was heated at 80°C. for 36 hours in a sealed
tube. After cooling the reaction vessel to -78°C., the plug
15 was removed and the ammonia was allowed to evaporate
while warming to room temperature. The residue was taken
up in EtOAc (30 ml) and filtered through a plug of celite.
Concentration in vacuo gave a clear, yellow oil that was
purified by flash chromatography, using EtOAc, through a
160 mm x 1 mm column of silica to give the desired amide.

-42-

Example 12

Cyclopentane N, N-dimethylheptenamide-5-cis
-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3,
5 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

A solution of the methyl ester of Example 10 (29.1 mg, 0.0723 mmol) and methanol (MeOH) (2 ml) in dimethylamine (8 ml) was heated at 80-85° C. for 36 hours.

10 After cooling to room temperature the sealed tube was opened and the excess amine was allowed to evaporate. Concentration of the residue in vacuo followed by flash chromatography with 10% EtOAc/MeOH through a 20 mm x 120 mm column of silica to yield the named amide as 9.2 mg

15 of a clear, slightly yellow oil and 14.8 mg of the recovered ester. Similarly the N-isopropyl, N-methyl and N-ethyl derivative can be prepared by substituting isopropylamine, methylamine and ethylamine, respectively for dimethylamine.

20

Example 13

Cyclopentane hepteneamine-5-cis-2-
(3- α -hydroxy-5-phenyl-1-trans-pentenyl)-3,
5 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

To a solution of the amide of Example 11 in tetrahydrofuran (THF) at 0° C. was added dropwise a stock solution of lithium aluminumhydride (LiAlH) in THF. The
10 reaction turned turbid white during this addition. After 2 hours, the reaction was removed from the cold bath and allowed to warm to room temperature over 15 minutes. Upon reaching room temperature, the reaction was quenched by cautious addition of 1N HCl (~0.5 ml) then
15 concentrated in vacuo to remove the THF. The residue was digested with ~1 ml of 0.5 ml LiOH, then extracted into chloroform (5 ml). The chloroform layer was then concentrated in vacuo. Flash chromatography using an 8:1:1 EtOAc: MeOH: triethylamine (Et₃N) through a 10 mm x 100
20 mm column of silica gel gave the desired amine as 10.7 mg of a clear oil. The oil was evaporated to constant weight on high vacuum overnight. Similarly, the 1-dimethylamino derivative can be prepared by substituting the 1-dimethylamido derivative of Example 12 for the amide of
25 Example 11.

Example 14

Cyclopentane heptenol-5-cis-2-
(3- α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

To a solution of cyclopentane heptenoic acid-5-cis-2-
(3 α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy,
[1 α , 2 β , 3 α , 5 α] in ethyl ether (Et₂O) was added a CH₂N₂
10 solution until the mixture turned yellow. The mixture was
then quenched with acetic acid until colorless. The solvents
were removed under vacuum and residue pumped down on
high vacuum for several hours. The resulting methyl ester
was then taken up in CH₂Cl₂ and cooled to -78° C. in a dry
15 ice/acetone bath. A dibutylaluminum hydride solution was
then added hourly and the resulting reaction was allowed to
warm to room temperature over 5 hours. The mixture was
then quenched with MeOH. The resulting solution was
transferred to a flask and diluted with ~5ml CH₂Cl₂. ~5 ml of
20 a saturated potassium sodium tartrate tetrahydrate solution
was added and the resulting cloudy mixture was allowed to
stir for 3 hours at which time the solution had cleared and
the organic and water layers has separated. The mixture
was transferred to a separatory funnel and separated. The
25 organic layer was washed, consecutively, with ~5 ml of H₂O
and ~5 ml of brine, dried over MgSO₄ and concentrated to
yield a yellow oil. Flash chromatography over SiO₂, with an
eluant varying from 1% MeOH/CH₂Cl₂ to 5% MeOH/CH₂Cl₂
gave 32.2 mg of the desired product as a colorless oil.

30

-45-

Example 15

Cyclopentane heptenol-5-cis-2-
(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)
5 -3, 5 dihydroxy, [1 α ,2 β ,3 α ,5 α]

To a solution of cyclopentane heptenoic acid-5-cis-2-
(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy,
[1 α ,2 β ,3 α ,5 α] (24.0 mg, 0.0565 mmol) in THF at 0° C. was
10 added a stock solution of LiAlH (1.0 M, 0.11 ml, 0.11 mmol).
The resulting mixture was maintained at 0° C. for 2 hours,
then was quenched by addition of 1N HCl (~0.2 ml). The
reaction was transferred into a separatory funnel with the
aid of brine (5 ml) and CHCl₃ (10 ml). The layers were
15 separated and the aqueous portion was further extracted
with two 5ml portions of CHCl₃. The combined organic
layers were then concentrated and purified by passing
through a column of silica using 5% MeOH in EtOAc as the
eluant.

20

Example 16

5 Cyclopentane heptenol-5-cis-2-
 (3- α tetrahydro-2H-pyran-2-yloxy-
 5-phenyl-1-trans-pentenyl)-3,5 di-tetra
 hydro-2-H-pyran-2-yloxy, [1 α ,2 β ,3 α ,5 α]

10 A "protected" methylsulfonate ester of the named
 compound of Example 14 is prepared by preparing a
 derivative of said named compound, wherein said hydroxyl
 groups are protected by conversion into tetrahydropyranyl
 derivatives, by methods known in the art. For example, see
 U.S. Patent 4,154,949 to Johnson et al, which issued 15 May
15 1979. Said derivatives are diluted in methylene chloride,
 cooled to 0° C., Et₃N and CH₃SO₂Cl are consecutively added
 and the organic layer is extracted and dried over MgSO₄.
 The solvent is evaporated to yield the methylsulfonate ester
 of the "protected" derivative. Similarly, the methylsulfonate
20 ester of the "protected" derivative of Example 15 may be
 prepared by substitution of the named compound of
 Example 15 in the above preparation.

-47-

Example 17

Cyclopentane heptenyliodide-5-cis-2-
(3- α -hydroxy-5-phenyl-1-trans-pentenyl)
5 -3,5 dihydroxy, [1 α ,2 β ,3 α ,5 α]

The "protected" compound of Example 16 is dissolved in acetone and then NaI and CaCO₃ are added. The mixture is stirred at room temperature over the weekend, filtered to
10 remove CaCO₃ and then worked up with EtOAc, brine and H₂O. The aqueous layer is extracted with EtOAc, the extract combined with the organic layer and concentrated. The concentrate is dried over MgSO₄. The resulting product is recovered by evaporation of the remaining solvent. The
15 resulting "protected" 1-iodide product is "deprotected" by dissolving in a mixture of MeOH and pyridinium-p-toluene sulfonate (PPTS) and heated, with stirring, to 50°C. The resulting solution is consecutively extracted with 10% citric acid, EtOAc, brine and NaHCO₃. The aqueous layer is
20 extracted with EtOAc, the extract combined with the organic layer, concentrated and dried over MgSO₄. Upon evaporation the named compound is obtained. Similarly, the 4-m-chlorophenoxy-1-trans-butenyl derivative may be obtained by substitution of the methylsulfonate ester of the
25 "protected" derivative of the compound of Example 15 in this preparation.

-48-

Example 18

Cyclopentane hepteneazide-5-cis-2-
(3- α -hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

The named compound is prepared by dissolving the "protected" compound of Example 16 in a solution of NaN₃ in dimethyl formamide (DMF) and stirring at room
10 temperature for 20 hours. The resulting mixture is consecutively extracted with water, brine and EtOAc. The aqueous layer is extracted with EtOAc, the extract combined with the organic layer, concentrated and dried over MgSO₄.
15 The solvent is evaporated and the residue is purified by chromatography using a solvent of 20% EtOAc in hexane. The resulting "protected" product is "deprotected" to yield the named compound by the procedure set forth in Example 17, above.

20

-49-

Example 19

Cyclopentane methoxyheptene-5-cis-2-
(3- α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 4 α , 5 α]

A solution of the "protected" compound of Example 16 in DMF is added dropwise to solution of NaH in DMF maintained under nitrogen at 0°C with stirring. Stirring is
10 continued and the solution is allowed to reach room temperature and stirring is continued for 15 minutes. The solution is then cooled to 0°C. and methyl iodide is added and the solution is allowed to warm to room temperature. The resulting mixture is consecutively extracted with 10% citric
15 acid, brine and EtOAc. The resulting aqueous layer is extracted with EtOAc, the extract is combined with the organic layer and the combination is dried over MgSO₄. Upon evaporation of the solvent a crude product including the tetrahydropyranyl derivative of the named compound is
20 obtained. The crude product is purified by thin liquid chromatography (TLC) using a solvent comprising 30 to 40 percent EtOAc in hexane. The resulting hydropyranyl derivative is "deprotected" by use of the procedure of Example 17. The "deprotected" product is purified by TLC
25 using a solvent comprising 1 to 5 percent acetic acid in EtOAc.

-50-

Example 20

Cyclopentane heptenyl fluoride-5-cis-2-(3-
 α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

The 0.098 mmoles of the compound of Example 16 (as derived from the Compound of Example 14) is dissolved into a 1.0 m. solution of tetrabutyl ammonium fluoride (Bu₄NF) in THF and stirred at room temperature overnight. (The total amount of Bu₄NF is 0.196 mmoles.) TLC shows substantial sulfonate remained so an additional 2.0 m. (4 m. total) of Bu₄NF is added. The mixture is stirred at room temperature for an additional 8 hours at which time it is then warmed up using H₂O, brine and EtOAc. The aqueous layer was extracted 3 times 10ml. with EtOAc while the organic layer was concentrated, and dried using MgSO₄. The solvents were evaporated to yield 65 mgs. of the "protected" derivative of the named compound. The "protected" derivative of the named compound is purified using a 20% EtOAc/Hexane. The "protected" derivative of the named compound is "deprotected" by use of the method of Example 17 to yield the named compound.

-51-

Example 21

Cyclopentane heptenyl nitrate-5-cis-2-(3-
 α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

The named compound is prepared by substituting
NaNO₂ in the method of Example 20. Alternatively, the
named compound is prepared by reacting the "protected" 1-
10 iodide product of Example 17 with NaNO₂ in
dimethylsulfoxide (DMSO) and "deprotecting" the resulting
product as shown in Example 17.

-52-

Example 22

5 Cyclopentane heptenecyanide-5-cis-2-(3-
 α hydroxy-5-phenyl-1-trans-pentenyl)
 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

The named compound is prepared by substituting NaCN in the method of Example 20.

-53-

Example 23

Cyclopentane heptene-5-cis-2-(3-
 α hydroxy-5-phenyl-1-trans-pentenyl)
5 -3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]


0.293 mmoles of cyclopentafuran -2-one, 5-tetrahydropyranyloxy, 4-(3-tetrahydropyranyloxy-1-octene) is dissolved in CH₂Cl₂, cooled to -78° C. and 1.0 Molar
10 DiBAH in CH₂Cl₂ is added until 0.586 mmole of DiBAH is in solution. Stirring is continued for 2 hours and the reaction mixture is quenched with methanol. The quenched mixture is washed into a separatory funnel with 10 ml of CH₂Cl₂ and washed with water. Acetic acid is added until the layers
15 separate. The organic layer is washed with brine. The combined water layers are washed twice with C₂Cl₂. The combined organic layers are dried over MgSO₄ and concentrated to yield a lactol derivative. 0.331 mmols of the lactol derivative are added to a solution of 0.993 mmols,
20 each, of (triphenyl) (n-pentyl) phosphonium bormide and KN(Si(CH₃)₃)₂ in THF at -78° C. The resulting solution is allowed to warm to room temperature, overnight, and then separated with 20 ml of EtOAc and washed with dilute acetic acid, water and brine, consecutively. The organic layer is
25 dried over Mg₂SO₄ and concentrated to yield a yellow oil which is purified by TLC with EtOAc/Hexane. The resulting "protected" derivative is "deprotected" by the method of Example 17 to yield cyclopentane heptene-5-cis-2-(3- α hydroxy-5-octenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α].
30 The named compound is prepared by substituting the phenyl pentenyl derivative for the above named cyclopentafuran-2-one.

-54-

The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent from one of ordinary skill in the art
5 that further compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions
10 may be prepared and used with substantially the same results. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended
15 claims.

CLAIMS

1. A method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula I



10 wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups, B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group


15 consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteratom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, X is a radical selected from the group consisting of halo, hydryl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, alkoxy and thio ether radicals; one of R₁ and R₂ is =O, -OH or a -O(CO)R₆ group, and the other one is -OH or -O(CO)R₆, or R₁ is =O and R₂ is H; wherein R₆ is a saturated or

20 unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or -(CH₂)_mR₇ wherein m is 0-10, and R₇ is cycloalkyl radical, having from to three seven

25 carbon atoms, or a hydrocarbyl aryl or heteroaryl, as


defined above; or a pharmaceutically-acceptable salt thereof.

2. The method of claim 1 wherein said compound is a compound of formula II.




10 wherein y is 0 or 1 and either the α or ω chain may be unsaturated, Y is a radical selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy, n is 0 or an integer of from 1 to 3 R_3 and is $=O$, $-OH$ or $-O(CO)R_6$.

3. The method of claim 2 wherein said compound is a compound of formula III.




wherein hatched lines indicate α configuration and solid triangles indicate β configuration.

4. The method of claim 3 wherein said compound is a compound of formula IV.




5. The method of claim 4 wherein said compound is a compound of formula V



and the 9- and/or 11- and/or 15 esters, thereof.

6. The method of claim 1 wherein X is selected from the group consisting of



7. The method of claim 6 wherein R_4 is hydrogen.

8. The method of claim 6 wherein said compound is selected from the group consisting of:

5 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]

10 cyclopentane N,N-dimethylheptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyl methoxide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

15

cyclopentane heptenyl fluoride-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

20 cyclopentane heptenyl nitrate-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyliodide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

25

cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

30 cyclopentane heptenecyanide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane hepteneazide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

35 cyclopentane heptene-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]

cyclopentane N-isopropyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

40 cyclopentane N-ethyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

45 cyclopentane N-methyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

50 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
and

55 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}].

9. The method of claim 7 wherein X is selected from the group consisting of hydroxyl, amino and amido radicals.

10. The method of claim 8 wherein said compound is selected from the group consisting of:

cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

5

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

10

cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

15


cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}] and

20

cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}].

11. A method of treating cardiovascular, pulmonary-respiratory, gastrointestinal, reproductive and allergic diseases and shock in a human which comprises administering to said human an effective amount of a compound of formula I


5



10


wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups, B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, X is a radical selected from the group consisting of halo, hydryl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, alkoxy and thio ether radicals; one of R_1 and R_2 is =O, -OH or a $-O(CO)R_6$ group, and the other one is -OH or $-O(CO)R_6$, or R_1 is =O and R_2 is H; wherein R_6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or $-(CH_2)_mR_7$ wherein m is 0-10, and R_7 is cycloalkyl radical, having from to three seven carbon atoms, or a hydrocarbyl aryl or heteroaryl, as defined above; or a pharmaceutically-acceptable salt thereof.

12. The method of claim 11 wherein said compound is a compound of formula II.




wherein y is 0 or 1 and either the α or ω chain may be unsaturated, Y is a radical selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy, n is 0 or an integer of from 1 to 3 and R_3 is $=O$, $-OH$ or $-O(CO)R_6$.

13. The method of claim 12 wherein said compound is a compound of formula III.



wherein hatched lines indicate α configuration and solid triangles indicate β configuration.


14. The method of claim 13 wherein said compound is a compound of formula IV.



15. The method of claim 14 wherein said compound is a compound of formula V

63

5



and the 9- and/or 11- and/or 15 esters, thereof.

16. The method of claim 11 wherein X is selected from the group consisting of

5

$$\begin{array}{c} \text{O} \\ || \\ -\text{CH}_3, -\text{F}, -\text{I}, -\text{NO}_2, -\text{OH}, -\text{OH}, -\text{C}-\text{N}(\text{R}_4)(\text{R}_4), -\text{N}(\text{R}_4)(\text{R}_4), =\text{N}-\text{OH}, -\text{C}\equiv\text{N}, -\text{Si} \\ \text{and } -\text{OR}_5 \text{ wherein } \text{R}_4 \text{ is hydrogen or } \text{C}_1 \text{ to } \text{C}_3 \text{ alkyl, and } \text{R}_5 \text{ is} \\ \text{C}_1 \text{ to } \text{C}_3 \text{ alkyl.} \end{array}$$

17. The method of claim 16 wherein R_4 is hydrogen.

18. The method of claim 6 wherein said compound is selected from the group consisting of:

5
 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α , 2_β , 3_α , 5_α];

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_α , 2_β , 3_α , 5_α];

10
 cyclopentane N,N-dimethylheptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α , 2_β , 3_α , 5_α];

cyclopentane heptenyl methoxide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α , 2_β , 3_α , 5_α];

- 15 cyclopentane heptenyl fluoride-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- cyclopentane heptenyl nitrate-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- 20 cyclopentane heptenyliodide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- 25 cyclopentane heptenecyanide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- cyclopentane hepteneazide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- 30 cyclopentane heptene-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- cyclopentane N-isopropyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- 35 cyclopentane N-ethyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];
- 40 cyclopentane N-methyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

45 cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-
chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-
chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
50 and

 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3,
5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}].

19. The method of claim 17 wherein X is selected from
the group consisting of hydroxyl, amino and amido radicals.

20. The method of claim 18 wherein said compound is
selected from the group consisting of:

5 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-
pentenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-
trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];


10 cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-
trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

15 cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-
chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-
chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}]
and

20 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3,
5 dihydroxy, [1 α , 2 β , 3 α , 5 α].


21. A pharmaceutical composition for treating ocular hypertension which comprises a therapeutically-effective amount of a compound of formula I



10 wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkoxy or alkylcarboxy groups, B is a
15 cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, X is a radical selected from the
20 group consisting of halo, hydryl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, alkoxy and thio ether radicals; one of R₁ and R₂ is =O, -OH or a -O(CO)R₆ group, and the other one is -OH or -O(CO)R₆, or R₁ is =O and R₂ is H;
25 wherein R₆ is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or -(CH₂)_mR₇ wherein m is 0-10, and R₇ is cycloalkyl radical, having from three to seven carbon atoms, or a


hydrocarbyl aryl or heteroaryl, as defined above; or a
 pharmaceutically-acceptable salt thereof in combination
 with an ophthalmically-acceptable vehicle.

22. The composition of claim 21 wherein said compound
 is a compound of formula II.




wherein y is 0 or 1 and either the α or ω chain may be
 unsaturated, Y is a radical selected from the group
 consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and
 alkylcarboxy, n is 0 or an integer of from 1 to 3 R_3 and is
 $=O$, $-OH$ or $-O(CO)R_6$.

23. The composition of claim 22 wherein said compound
 is a compound of formula III.




wherein hatched lines indicate α configuration and solid
 triangles indicate β configuration.

24. The composition of claim 23 wherein said compound is a compound of formula IV.



25. The composition of claim 24 wherein said compound is a compound of formula V



and the 9- and/or 11- and/or 15 esters, thereof.

26. The composition of claim 21 wherein X is selected from the group consisting of

O
||

-CH₃, -F, -I, -NO₂, -OH, -OH, -C-N(R₄)(R₄), -N(R₄)(R₄), =N-OH, -C≡N, -Si
and -OR₅ wherein R₄ is hydrogen or C₁ to C₃ alkyl, and R₅ is
C₁ to C₃ alkyl.

27. The composition of claim 26 wherein R₄ is hydrogen.

28. The composition of claim 26 wherein said compound is selected from the group consisting of:

5 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

10 cyclopentane N,N-dimethylheptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

15 cyclopentane heptenyl methoxide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyl fluoride-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

20 cyclopentane heptenyl nitrate-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyliodide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

25 cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

30 cyclopentane heptenecyanide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane hepteneazide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptene-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

35

cyclopentane N-isopropyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane N-ethyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

40

cyclopentane N-methyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

45

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α] and

50

cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α].

29. The composition of claim 27 wherein X is selected from the group consisting of hydroxyl, amino and amido radicals.

30. The composition of claim 28 wherein said compound is selected from the group consisting of:

cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

5

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];


10 cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}];

15 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}] and

20 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)-3, 5 dihydroxy, [1_{α} , 2_{β} , 3_{α} , 5_{α}].


31. A compound selected from the group consisting of compounds represented by formula I



10 wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be substituted with one or

more hydroxy, oxo, alkyloxy or alkylcarboxy groups, B is a
 cycloalkyl radical having from three to seven carbon atoms,
 or an aryl radical, selected from the group consisting of
 hydrocarbyl aryl and heteroaryl radicals wherein the
 heteroatom is selected from the group consisting of nitrogen,
 oxygen and sulfur atoms, X is a radical selected from the
 group consisting of halo, hydryl, hydroxyl, nitro, amino,
 amido, azido, oxime, cyano, thiol, alkoxy and thio ether
 radicals; one of R_1 and R_2 is $=O$, $-OH$ or a $-O(CO)R_6$ group, and
 the other one is $-OH$ or $-O(CO)R_6$, or R_1 is $=O$ and R_2 is H ;
 wherein R_6 is a saturated or unsaturated acyclic
 hydrocarbon group having from 1 to about 20 carbon
 atoms, or $-(CH_2)_mR_7$ wherein m is 0-10, and R_7 is cycloalkyl
 radical, having from three to seven carbon atoms, or a
 hydrocarbyl aryl or heteroaryl, as defined above; or a
 pharmaceutically-acceptable salt thereof in combination
 with an ophthalmically-acceptable vehicle.


32. A compound according to claim 31 wherein said
 compound is a compound of formula II.



wherein y is 0 or 1 and either the α or ω chain may be
 unsaturated, Y is a radical selected from the group
 consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and


alkylcarboxy, n is 0 or an integer of from 1 to 3 R_3 and is $=O$, $-OH$ or $-O(CO)R_6$.

33. A compound according to claim 32 wherein said compound is a compound of formula III.




wherein hatched lines indicate α configuration and solid triangles indicate β configuration.

34. A compound according to claim 33 wherein said compound is a compound of formula IV.



35. The composition of claim 34 wherein said compound is a compound of formula V



and the 9- and/or 11- and/or 15 esters, thereof.

36. A compound according to claim 31 wherein X is selected from the group consisting of -CH₃, -F, -I, -NO₂, -OH, -OH, -C-N(R₄)(R₄), -N(R₄)(R₄), =N-OH, -C≡N, -S, and -OR₅ wherein R₄ is hydrogen or C₁ to C₃ alkyl, and R₅ is C₁ to C₃ alkyl.

5

37. A compound according to claim 36 wherein R₄ is hydrogen.

38. A compound according to claim 36 wherein said compound is selected from the group consisting of:

cyclopentane heptenol-5-cis-2-(3-αhydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1_α, 2_β, 3_α, 5_α];

5

cyclopentane heptenamide-5-cis-2-(3-αhydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1_α, 2_β, 3_α, 5_α];

10 cyclopentane N,N-dimethylheptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyl methoxide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

15 cyclopentane heptenyl fluoride-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

20 cyclopentane heptenyl nitrate-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenyliodide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

25 cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenecyanide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

30 cyclopentane hepteneazide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

35 cyclopentane heptene-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane N-isopropyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

40 cyclopentane N-ethyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane N-methyl heptene amide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

45 cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

50 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α] and

cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α].

39. A compound according to claim 38 wherein X is selected from the group consisting of hydroxyl, amino and amido radicals.

40. A compound according to claim 38 wherein said compound is selected from the group consisting of:

5 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pentenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenamide-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

10 cyclopentane hepteneamine-5-cis-2-(3- α hydroxy-5-phenyl-1-trans-pent-enyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

cyclopentane heptenol-5-cis-2-(3- α hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α];

15 cyclopentane heptenamide-5-cis-2-(3- α hydroxy-4-m-
chlorophenoxy-1-trans-butenyl)-3, 5 dihydroxy, [1 α , 2 β , 3 α , 5 α]
and

20 cyclopentane heptenol-5-cis-2-(3- α hydroxy-5-phenylpentyl)3,
5 dihy-droxy, [1 α , 2 β , 3 α , 5 α].

1/3




FIG. 1.

FIG. 2.

3 / 3

FIG. 3.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K31/557

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO, A, 90 02553 (PHARMACIA AB) 22 March 1990 see page 4, paragraph 4; claims ---	1-40
X, Y	EP, A, 0 453 127 (K.K. UENO SEIYAKU OYO KENKYUJO) 23 October 1991 see page 1, line 37 - line 46 see page 3, line 8 - line 11 see page 3, line 31 - page 4, line 25 see page 5, line 27 - line 41; claim 1 ---	1-40
X Y	FR, A, 2 386 523 (SCHERING) 3 November 1978 see page 14, line 11; claims ---	31-40 1-40
X	DE, A, 27 21 534 (CARLO ERBA) 15 December 1977 see claims ---	31-40
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 January 1994

Date of mailing of the international search report

03.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

BERTE, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR,A,2 312 240 (SCHERING AG.) 24 December 1976	31-40
Y	see page 26, line 22 - line 29; claims ---	1-40
X	US,A,4 171 331 (W. C. BIDDLECOM) 16 October 1979 see column 17 - column 28; claims; figures; examples ---	31-40
X	LU,A,68 940 (ICI LTD.) 12 February 1974 see claims ---	31-40
Y	EP,A,0 253 094 (RESEARCH DEV. CO. OF JAPAN) 20 January 1988 see page 3, line 20 - line 21; claims ---	1-40
X	PROSTAGLANDINS vol. 13, no. 5 , May 1977 , STONEHAM, MA US pages 837 - 843. H. C. ARNDT 'THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF PROSTAGLANDINS ANALOGS CONTAINING SPIROCYCLIC RINGS' see page 841; figures 1,11 ---	31-40
Y	WO,A,92 08465 (ALLERGAN INC.) 29 May 1992 see claims ---	1-40
X	TETRAHEDRON: ASYMMETRY vol. 32 , 1976 , OXFORD GB pages 2747 - 2752 P. DE CLERCQ ET AL. 'CYCLOPENTANONES-XV1 . PROSTAGLANDIN SYNTHESIS INVOLVING CATALYTIC HYDROGENATION OF 2,3-DIALKYL-4-HYDROXY-2-CYCLOPENTENONES' see figures 1,3 -----	31-40

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/08472

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-40
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
In view of the definition of products by means of their biological, chemical and or pharmacological properties, the search has to be restricted for economical reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims or examples.
(SEE GUIDELINES, PART B, CHAPTER III, PARAGRAPH 3.6)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9002553	22-03-90	AU-B- 625096	02-07-92
		AU-A- 4189889	02-04-90
		EP-A- 0364417	18-04-90
		EP-A- 0569046	10-11-93
		JP-T- 3501025	07-03-91
		SE-A- 8803855	28-10-88

EP-A-0453127	23-10-91	AU-B- 644148	02-12-93
		AU-A- 7404791	10-10-91
		JP-A- 5058992	09-03-93
		US-A- 5212324	18-05-93
		JP-A- 4253909	09-09-92

FR-A-2386523	03-11-78	DE-A- 2715838	19-10-78
		BE-A- 865705	05-10-78
		CH-A- 638773	14-10-83
		GB-A- 1601994	04-11-81
		JP-A- 53124238	30-10-78
		LU-A- 79369	13-07-78
		NL-A- 7803415	09-10-78

DE-A-2721534	15-12-77	AT-B- 356302	25-04-80
		AT-B- 367747	26-07-82
		AU-B- 509127	24-04-80
		AU-A- 2465677	02-11-78
		BE-A- 855236	30-11-77
		CA-A- 1115700	05-01-82
		CH-A- 634831	28-02-83
		FR-A, B 2368473	19-05-78
		GB-A- 1583263	21-01-81
		JP-C- 1373173	07-04-87
		JP-A- 52148044	08-12-77
		JP-B- 61040662	10-09-86
		NL-A- 7705701	05-12-77
		SE-B- 436026	05-11-84
		SE-A- 7706310	02-12-77
		SU-A- 932985	30-05-82
		US-A- 4195183	25-03-80

FR-A-2312240	24-12-76	DE-A- 2523676	16-12-76

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2312240		DE-A- 2616304	03-11-77
		AT-B- 359657	25-11-80
		AU-B- 510695	10-07-80
		AU-A- 1422576	01-12-77
		BE-A- 842276	26-11-76
		CA-A- 1091226	09-12-80
		CH-A- 623036	15-05-81
		GB-A- 1553710	26-09-79
		JP-A- 51143643	10-12-76
		LU-A- 75011	20-01-77
		NL-A- 7605381	30-11-76
		SE-A- 7605925	27-11-76
		US-A- 4105792	08-08-78
		US-A- 4256745	17-03-81
		US-A- 4159343	26-06-79

US-A-4171331	16-10-79	NONE	

LU-A-68940	12-02-74	GB-A- 1402035	06-08-75
		AU-B- 473283	17-06-76
		AU-A- 6279773	27-11-75
		BE-A- 808398	07-06-74
		CA-A- 1016940	06-09-77
		CH-A- 605725	13-10-78
		DE-A- 2360893	12-06-74
		FR-A, B 2209569	05-07-74
		JP-A- 50024252	15-03-75
		NL-A- 7316508	11-06-74

EP-A-0253094	20-01-88	JP-A- 63107927	12-05-88
		US-A- 4824857	25-04-89

WO-A-9208465	29-05-92	US-A- 5270049	14-12-93
		AU-A- 9041491	11-06-92
		EP-A- 0556296	25-08-93